has received US FDA approval for the treatment of several cancers.
a biosimilar to the monoclonal antibody bevacizumab, received FDA-Approval
for several advanced cancers
is a monoclonal antibody that prevents the growth of blood vessels
- Its introduction
in the market as a competition to bevacizumab could bring down the cost of
treatment, thus benefiting patients.
introduction of a competitor to bevacizumab could possibly help to reduce cost
of treatment and increase the availability of the medication, thus ensuring
that more patients experience the benefits of the treatment.
Bevacizumab-awwb has been approved for
the treatment a wide variety of advanced cancers in adult patients, which
- Metastatic colorectal cancer, which is a late-stage cancer of the large intestine or rectum. 'Metastatic' refers to cancer that has spread
to other sites. When used for this purpose, bevacizumab-awwb should be used in
combination with chemotherapy that includes:
5-fluorouracil as a first- or second-line treatment or
- Fluoropyrimidine and irinotecan or oxaliplatin as second-line treatment in patients who had
progressed despite earlier treatment with a bevacizumab product-containing
It should not be used to
improve outcomes in patients who have undergone resection of colorectal cancer.
‘Bevacizumab-awwb has received FDA approval for the treatment of several advanced cancers.’
locally advanced, recurrent or metastatic non-squamous non-small cell lung
as a first option along with the anticancer drugs carboplatin and paclitaxel.
Most lung cancers are non-small cell lung cancers. The non-squamous cell type
include the subtypes beside the squamous cell subtype, like adenocarcinoma and
large cell carcinoma
- Glioblastoma, a type of
brain cancer, which has progressed despite earlier treatment. Glioblastoma
arises from astrocytes, the cells that form the supportive tissue of the brain
recurrent, or metastatic cervical cancer, along with paclitaxel
and cisplatin or paclitaxel and
should not be used as a substitute for bevacizumab.
The side effects caused
by bevacizumab-awwb range from mild to severe. The common adverse effects that
may be expected from the treatment, include bleeds from
the nose or rectum or other organs which can be severe, high blood pressure,
tearing of eyes and running of nose, loss of protein through the urine, a skin
condition called exfoliative dermatitis, headache, alteration in taste and back
pain. In addition, it has also been associated with perforation of an organ,
blood clot formation in the arteries or veins, a brain condition called
posterior reversible encephalopathy syndrome, ovarian failure, and
infusion-related reactions. Problems with wound healing following surgery could
occur, and therefore bevacizumab-awwb should not be taken around a month before
and after surgery. It should not be administered to pregnant women.
BevacizumabBevacizumab is a
monoclonal antibody, classified as a vascular endothelial growth factor (VEGF)
inhibitor. It prevents the development of blood vessels in cancer and slows
its growth. It has several off-label uses that include age-related macular
degeneration, metastatic breast cancer, recurrent endometrial cancer and
hereditary hemorrhagic telangiectasia. Products like bevacizumab are classified
as biologicals since they are obtained from a living organism.
- FDA approves first biosimilar for the treatment of cancer - (https:www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm576112.htm)